Dr. Albert J (Arjan) Bredenoord studied Medicine in Antwerp, Belgium. He subsequently worked on several clinical research projects on gastrointestinal motility at the University of Utrecht, the Netherlands which resulted in the completion of his PhD thesis on gastroesophageal reflux disease in 2006. His clinical training was performed in Nieuwegein, the Netherlands and at the Royal London Hospital in London, UK. He currently works as a consultant Gastroenterologist at the Amsterdam University Medical Center where he is dedicated to patients’ care, scientific research and education in the field of benign esophageal diseases. He was appointed professor of Neurogastroenterology & Motility at the University of Amsterdam in 2019.

Dr. Bredenoord’s main focus is on achalasia, reflux disease and eosinophilic esophagitis. The esophageal clinic in the AMC Amsterdam hosts the largest population of benign esophageal diseases in the Netherlands. Dr Bredenoord is an author of over 250 papers, books and book chapters on esophageal diseases and organizes regular courses in Europe, North America and Asia. Dr Bredenoord is President of the European Society of Eosinophilic Esophagitis EUREOS, a member of the UEG Scientific Committee and co-founder of the International HRM working group. He collaborates with Alimentiv on studies on endpoint development for clinical trials in eosinophilic esophagitis and advises on all stages of trial design in drug development for eosinophilic esophagitis.

Evan S. Dellon, MD, MPH, is a Professor of Medicine and Adjunct Professor of Epidemiology at the University of North Carolina School of Medicine at Chapel Hill.

Dr. Dellon received his undergraduate degree from Brown University and his medical degree from the Johns Hopkins School of Medicine. He completed his internship and residency in Internal Medicine at Massachusetts General Hospital. He performed a clinical and a research fellowship in Adult Gastroenterology at UNC, during which he also received a Masters of Public Health degree in Epidemiology from the UNC School of Public Health.

Dr. Dellon joined the UNC faculty and the Center for Esophageal Diseases and Swallowing (CEDAS) in 2008, where his main clinical focus is on disorders of swallowing, and in particular eosinophilic esophagitis (EoE) and other eosinophilic gastrointestinal diseases (EGIDs). He became Director of CEDAS in 2014.

Dr. Dellon’s research interests span the epidemiology, pathogenesis, diagnosis, treatment, and outcomes of EoE and EGIDs. The goal of his research is to improve the lives of patients with EoE/EGIDs by learning how to better diagnose, treat, and monitor the conditions. He is widely published in this area, with more than 265 peer-reviewed papers in the medical literature overall.

Dr. Dellon is also an Associate Editor for Clinical Gastroenterology and Hepatology. He collaborates with and advises Alimentiv Clinical Trials on studies related to EoE and EGIDs, including the areas of trial design, patient outcomes, and endpoint development.

Senior researcher at the Institute of Social and Preventive Medicine, University of Bern

Dr. Safroneeva obtained her B.Sc. from University of Toronto, ON, Canada, and Ph.D. in mucosal immunology from McMaster University, ON, Canada. She completed her postdoctoral fellowships in the Farncombe Family Digestive Health Research Institute, McMaster University, ON, Canada, and at the Institute of Social and Preventive Medicine, University of Bern. She is currently a senior researcher at the Institute of Social and Preventive Medicine, University of Bern.

The objective of her research is to study outcome assessment in adults with eosinophilic esophagitis (EoE). The team of international collaborators, with Dr. Safroneeva in the lead, has developed EoE activity index patient-reported outcomes instrument that has been used in various phase 2 and 3 clinical trials and observational studies. She explored patients’ perspective on therapy goals and satisfactions with various EoE therapies, and conducted epidemiologic studies including those on natural history, and time-dependent development of strictures and other complications. Together with clinicians and scientists of Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR), European Society of EoE Researchers (EUREOS), and Alimeniv Inc., the applicant led core outcome set development exercise to aid in standardization of outcome assessment in EoE. As lead investigator, the applicant has been involved in a number of Swiss- and US-based studies examining the relationship between various patient-reported measures and biologic activity.

Dr. Ma supports medical R&D projects.

Dr. Ma obtained his MD from the University of Calgary in 2012. He completed his Internal Medicine residency at the University of Alberta, adult gastroenterology training at the University of Calgary and advanced IBD fellowships at the University of Calgary and Western University. In 2018, he completed a one-year Robarts IBD Clinical Trials Fellowship and in 2019 he earned an  MPH in Epidemiology from Harvard University.